Celldex Therapeutics: Business Overview, Financials & Competitive Analysis
Celldex Therapeutics scores 7/10 on the AskCyborg Cyborg Score (Strong). With pipeline progress, clinical milestones, and premium pricing potential creating multiple catalysts, CLDX presents an attractive investment, offering both upside from near-term data readouts and long-term blockbuster potential across multiple indications.
What is Celldex Therapeutics's industry? Celldex Therapeutics (celldex.com) operates in Biopharmaceutical - Immunotherapy and Monoclonal Antibodies. AskCyborg classifies Celldex Therapeutics under Biopharmaceutical - Immunotherapy and Monoclonal Antibodies in its company registry.
Celldex Therapeutics is emerging as an attractive biotech pick for 2026, driven by its advancing immunology pipeline and promising clinical data. Barzolvolimab is a humanized monoclonal antibody with a completely nove...
Cyborg Score thesis
With pipeline progress, clinical milestones, and premium pricing potential creating multiple catalysts, CLDX presents an...
Read the full analyst-debate transcript →Get the Latest Celldex Therapeutics Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCelldex Therapeutics Overview
Pro stress-test →Celldex Therapeutics is emerging as an attractive biotech pick for 2026, driven by its advancing immunology pipeline and promising clinical data. Barzolvolimab is a humanized monoclonal antibody with a completely novel mechanism of action that uniquely targets the root cause of cold urticaria and symptomatic dermographism—the mast cell.
Strategic Profile
Pro stress-test →Barzo is uniquely positioned as a "pipeline in a drug," targeting multiple mast cell diseases and commanding potential premium pricing. Management suggests that barzo's durable efficacy—extending beyond a year of dosing—could support substantially higher reimbursement, comparable to Dupixent's $60,000 annual cost.
Competitive Landscape
Pro stress-test →Celldex is pioneering new horizons in immunology to deliver life-changing therapies, pursuing novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve lives of patients with allergic, inflammatory and autoimmune disorders. The mast cell-targeting immunology space includes competitors developing alternative approaches to urticaria and related conditions.
Industry Context
Celldex Therapeutics operates in Biopharmaceutical - Immunotherapy and Monoclonal Antibodies.
Key facts
Headquarters: Hampton, New Jersey, US · Revenue: $0.12M (Q4 2025) · Market cap: $2.02B